Spectara
Spectara develops fieldable detection systems and assays for rapid identification of biological threats in aerosols and early detection of individual infections. The company combines time-of-flight mass spectrometry–based aerosol analysis with protease-based biomarker assays to provide real-time, reagent-free detection for defense, public-health, and commercial customers. Spectara positions its technology for dual-use applications in biosecurity and clinical infection identification and reports government validation and deployments.
Industries
Nr. of Employees
small (1-50)
Patents
Diagnosis of respiratory diseases using analysis of exhaled breath and aerosols
US-12364411-B2
View DetailsMethods and systems for detecting aerosol particles without using complex organic MALDI matrices
US-11996280-B2
View Details
Diagnosis of respiratory diseases using analysis of exhaled breath and aerosols
US-12364411-B2
View DetailsMethods and systems for detecting aerosol particles without using complex organic MALDI matrices
US-11996280-B2
View DetailsProducts
Field-deployable time-of-flight mass spectrometer for edge bioaerosol detection
A fieldable ToF mass spectrometry instrument designed for autonomous aerosol collection and rapid identification of known biological threat agents with cloud-connected reporting.
Continuous triggerless particle-mass analysis system for agnostic detection
A continuous, triggerless mass spectrometry system that analyzes aerosol particles one-by-one without reagents to detect spikes in similar particles indicative of novel or emerging threats.
Protease-based non-invasive diagnostic assay for early infection detection
An assay methodology that detects host protease signals from non-invasive breath samples to identify infections earlier than conventional clinical diagnostics and to inform treatment decisions.
Field-deployable time-of-flight mass spectrometer for edge bioaerosol detection
A fieldable ToF mass spectrometry instrument designed for autonomous aerosol collection and rapid identification of known biological threat agents with cloud-connected reporting.
Continuous triggerless particle-mass analysis system for agnostic detection
A continuous, triggerless mass spectrometry system that analyzes aerosol particles one-by-one without reagents to detect spikes in similar particles indicative of novel or emerging threats.
Protease-based non-invasive diagnostic assay for early infection detection
An assay methodology that detects host protease signals from non-invasive breath samples to identify infections earlier than conventional clinical diagnostics and to inform treatment decisions.
Services
Collaborative projects to adapt detection hardware and assays for partner-specific applications, including development, validation, and deployment support.
Deployment, monitoring, and reporting services for continuous bioaerosol surveillance at edge locations and critical infrastructure.
Collaborative projects to adapt detection hardware and assays for partner-specific applications, including development, validation, and deployment support.
Deployment, monitoring, and reporting services for continuous bioaerosol surveillance at edge locations and critical infrastructure.
Expertise Areas
- Bioaerosol detection and biosurveillance
- Field-deployable mass spectrometry
- Agnostic/unknown-threat detection
- Protease-based diagnostic development
Key Technologies
- Time-of-flight mass spectrometry (ToF-MS)
- Particle-by-particle aerosol mass analysis
- Triggerless continuous sampling
- Protease biomarker assays
News & Updates
Recombination of prior business units under a single identity focused on biosecurity and individual infection identification.
NIH-funded research into non-invasive, population-scale pathogen screening approaches.
Recognition under the U.S. Small Business Administration SBIR/STTR programs for innovation in biological detection technology.
Recombination of prior business units under a single identity focused on biosecurity and individual infection identification.
NIH-funded research into non-invasive, population-scale pathogen screening approaches.
Recognition under the U.S. Small Business Administration SBIR/STTR programs for innovation in biological detection technology.